PubRank

Katherine L Nathanson

Author PubWeight™ 217.63‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010 16.12
2 The tuberous sclerosis complex. N Engl J Med 2006 13.53
3 Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010 12.50
4 Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002 9.71
5 A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 2010 4.96
6 HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008 4.84
7 PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011 4.80
8 Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 2015 4.77
9 Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 2007 4.69
10 Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013 4.35
11 Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer 2010 3.78
12 Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002 3.65
13 RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 2007 3.63
14 Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 2006 3.42
15 Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008 3.41
16 Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet 2009 2.85
17 The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008 2.64
18 Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 2013 2.39
19 Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol 2013 2.38
20 A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 2006 2.35
21 Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet 2006 2.23
22 Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2009 2.13
23 The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res 2011 2.09
24 ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat 2011 1.94
25 Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res 2007 1.89
26 Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet 2013 1.88
27 Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 2008 1.86
28 Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn 2007 1.85
29 Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin Cancer Res 2011 1.84
30 A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet 2013 1.82
31 Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat Genet 2013 1.74
32 Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 2014 1.74
33 The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol 2009 1.70
34 HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci U S A 2009 1.59
35 Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst 2003 1.58
36 Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet 2003 1.58
37 Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res 2009 1.57
38 Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet 2010 1.56
39 Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2011 1.51
40 Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Genet Test 2008 1.46
41 Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep 2013 1.43
42 Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med 2011 1.42
43 Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2010 1.41
44 Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurology 2010 1.39
45 Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res 2008 1.39
46 Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis 2012 1.38
47 Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res 2009 1.36
48 A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. Hum Mol Genet 2011 1.34
49 Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genet 2012 1.34
50 Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. Breast Cancer Res 2009 1.32
51 Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res 2009 1.30
52 Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov 2012 1.25
53 The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res 2008 1.24
54 Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A 2002 1.23
55 Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res 2011 1.22
56 Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. Hum Mol Genet 2013 1.19
57 Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer 2011 1.18
58 PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer 2011 1.18
59 Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012 1.17
60 Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2010 1.15
61 Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol 2011 1.12
62 Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res 2011 1.12
63 A genome-wide association study of breast cancer in women of African ancestry. Hum Genet 2012 1.11
64 BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol 2002 1.06
65 The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res 2013 1.06
66 Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. Genes Chromosomes Cancer 2008 1.05
67 Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res 2011 1.05
68 Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res 2009 1.04
69 Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res 2009 1.03
70 Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic. Cancer Biol Ther 2006 1.02
71 Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res 2009 1.01
72 Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2010 1.01
73 Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res 2014 0.99
74 Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat 2012 0.98
75 Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med 2005 0.98
76 Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer. Clin Cancer Res 2007 0.95
77 Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis 2013 0.95
78 Common breast cancer risk variants in the post-COGS era: a comprehensive review. Breast Cancer Res 2013 0.94
79 Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dubé syndrome. Genes Chromosomes Cancer 2011 0.94
80 Immunotherapy at large: the road to personalized cancer vaccines. Nat Med 2013 0.93
81 The molecular biology of renal cell carcinoma. Semin Oncol 2013 0.91
82 BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst 2015 0.90
83 The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One 2013 0.90
84 Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2014 0.89
85 Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer 2012 0.89
86 Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Hum Mol Genet 2011 0.89
87 A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012 0.89
88 Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet 2011 0.87
89 An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women. Genet Med 2005 0.87
90 Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity. Cancer Discov 2013 0.87
91 Predisposition alleles for Testicular Germ Cell Tumour. Curr Opin Genet Dev 2010 0.86
92 A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers. Cancer Epidemiol Biomarkers Prev 2006 0.86
93 Malignant paraganglioma associated with succinate dehydrogenase subunit B in an 8-year-old child: the age of first screening? Pediatr Nephrol 2009 0.86
94 The von Hippel-Lindau (VHL) germline mutation V84L manifests as early-onset bilateral pheochromocytoma. Am J Med Genet A 2006 0.84
95 Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev 2011 0.84
96 No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Res Treat 2008 0.84
97 Molecular testing in melanoma. Cancer J 2012 0.83
98 Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del. Cancer Res 2009 0.82
99 No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2008 0.82
100 Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res 2010 0.82
101 Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF). Front Endocrinol (Lausanne) 2012 0.81
102 The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma. Mol Cell Biol 2013 0.81
103 Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry. Breast Cancer Res Treat 2011 0.81
104 Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestry. Cancer Epidemiol Biomarkers Prev 2012 0.80
105 Younger age-at-diagnosis for familial malignant testicular germ cell tumor. Fam Cancer 2009 0.80
106 Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS One 2012 0.80
107 Hybrid peripheral nerve sheath tumor. J Neurosurg 2012 0.79
108 Germ-line DICER1 mutations do not make a major contribution to the etiology of familial testicular germ cell tumours. BMC Res Notes 2013 0.79
109 Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Res 2011 0.79
110 Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. PLoS One 2013 0.78
111 Resolving ATM haplotypes in whites. Am J Hum Genet 2003 0.78
112 The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2012 0.78
113 Taking the guesswork out of uveal melanoma. N Engl J Med 2010 0.76
114 Deletion of 15q11.2-15q13.1 in isolated human hemimegalencephaly. Acta Neuropathol 2009 0.76
115 Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. Breast Cancer Res Treat 2012 0.75
116 HNPCC-associated pheochromocytoma: expanding the tumor spectrum. Pancreas 2015 0.75
117 Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst 2017 0.75
118 Comparison of address-based sampling and random-digit dialing methods for recruiting young men as controls in a case-control study of testicular cancer susceptibility. Am J Epidemiol 2013 0.75
119 Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States. Clin Breast Cancer 2007 0.75